• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MiMedx Group Inc (Amendment)

    2/8/22 5:00:20 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email
    SC 13G/A 1 p22-0198sc13ga.htm MIMEDX GROUP, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  1)*
     

    MiMedx Group, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    602496101

    (CUSIP Number)
     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 11 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 60249610113G/APage 2 of 11 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Prescience Partners, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    6,119,888 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    6,119,888 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,119,888 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.5%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 60249610113G/APage 3 of 11 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Prescience Point Special Opportunity LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    1,666,233 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    1,666,233 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,666,233 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.5%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 60249610113G/APage 4 of 11 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Prescience Capital, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    7,786,121 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    7,786,121 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,786,121 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.9%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 60249610113G/APage 5 of 11 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Prescience Investment Group, LLC d/b/a Prescience Point Capital Management LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Louisiana

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    8,411,019 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    8,411,019 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,411,019 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

    CUSIP No. 60249610113G/APage 6 of 11 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Eiad Asbahi

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    8,411,019 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    8,411,019 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,411,019 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 60249610113G/APage 7 of 11 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is MiMedx Group, Inc. (the “Issuer”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer’s principal executive offices are located at 1775 West Oak Commons Ct NE, Marietta, GA 30062.

     

    Item 2(a). NAME OF PERSON FILING:
       
     

    This Statement is filed by:

     

      (i) Prescience Partners LP (“Prescience Partners”), a Delaware limited partnership, with respect to the Shares directly and beneficially owned by it;  
         
      (ii) Prescience Point Special Opportunity LP (“Prescience Point”), a Delaware limited partnership, with respect to the Shares directly and beneficially owned by it;  
         
      (iii) Prescience Capital, LLC (“Prescience Capital”), a Delaware limited liability company, as the general partner of each of Prescience Partners and Prescience Point;  
         
      (iv) Prescience Investment Group, LLC d/b/a Prescience Point Capital Management LLC (“Prescience Management”), a Louisiana limited liability company, as the investment manager of each of Prescience Partners and Prescience Point and the investment manager to certain managed accounts (the “Managed Accounts”); and  
         
      (v) Eiad Asbahi (“Mr. Asbahi”), as managing member of Prescience Management.  
         
      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the principal business office of each of the Reporting Persons is 1670 Lobdell Avenue, Suite 200, Baton Rouge, Louisiana 70806.

     

    CUSIP No. 60249610113G/APage 8 of 11 Pages

     

     

    Item 2(c). CITIZENSHIP:
       
      Prescience Partners and Prescience Point are Delaware limited partnerships.  Prescience Capital is a Delaware limited liability company.  Prescience Management is a Louisiana limited liability company.  Mr. Asbahi is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Shares”).
       
    Item 2(e). CUSIP NUMBER:
       
      602496101

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    CUSIP No. 60249610113G/APage 9 of 11 Pages

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:_________________________________

     

    Item 4. OWNERSHIP.
       
      The percentages used herein and in the rest of this Schedule 13G/A are calculated based upon a total of 112,144,444 Shares reported to be outstanding as of October 20, 2021 in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 2, 2021.
      The information required by Items 4(a) – (c)  is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    CUSIP No. 60249610113G/APage 10 of 11 Pages

     

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         

     

    CUSIP No. 60249610113G/APage 11 of 11 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 8, 2022

     

      Prescience Partners, LP
         
      By: Prescience Point Capital Management LLC
        Investment Manager
         
      By: /s/ Eiad Asbahi
      Name: Eiad Asbahi
      Title: Managing Member
       

     

      Prescience Point Special Opportunity LP
         
      By: Prescience Point Capital Management LLC
        Investment Manager
         
      By: /s/ Eiad Asbahi
      Name: Eiad Asbahi
      Title: Managing Member
       

     

      Prescience Capital, LLC
         
      By: /s/ Eiad Asbahi
      Name: Eiad Asbahi
      Title: Managing Member
       

     

      Prescience Point Capital Management LLC
         
      By: /s/ Eiad Asbahi
      Name: Eiad Asbahi
      Title: Managing Member
       

     

        /s/ Eiad Asbahi
        EIAD ASBAHI
         
       

     

    Get the next $MDXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    2/23/2026$10.00Mkt Outperform
    Citizens
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

    Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome

    6/2/26 9:00:00 AM ET
    $BVS
    $IART
    $MDXG
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

    MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare.

    5/21/26 8:45:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Launch of G4Derm® Plus

    Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets. "This launch showcases our efforts to leverage our sizable commercial reach to expand solutions available to clinici

    5/8/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    5/5/25 10:06:51 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    11/22/23 5:01:18 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 20,245 shares, decreasing direct ownership by 4% to 543,195 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    3/17/26 6:32:28 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 6,762 shares, decreasing direct ownership by 2% to 329,450 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    3/17/26 6:31:14 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Maersk-Moller Kimberly exercised 42,845 shares at a strike of $4.50 and covered exercise/tax liability with 21,270 shares, increasing direct ownership by 7% to 336,212 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    3/12/26 5:37:04 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $MDXG
    SEC Filings

    View All

    Citizens initiated coverage on MiMedx Group with a new price target

    Citizens initiated coverage of MiMedx Group with a rating of Mkt Outperform and set a new price target of $10.00

    2/23/26 8:37:40 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

    Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

    7/2/24 7:38:13 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on MiMedx Group with a new price target

    Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    3/7/24 8:26:30 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by MiMedx Group Inc

    DEFA14A - MIMEDX GROUP, INC. (0001376339) (Filer)

    4/29/26 4:25:11 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    4/29/26 4:01:07 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by MiMedx Group Inc

    DEF 14A - MIMEDX GROUP, INC. (0001376339) (Filer)

    4/29/26 4:02:32 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

    Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

    7/17/24 8:00:00 AM ET
    $MDXG
    $SAVA
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

    MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

    6/26/24 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Appointment of Two New Independent Directors

    MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

    3/4/24 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Financials

    Live finance-specific insights

    View All

    MIMEDX Announces First Quarter 2026 Operating & Financial Results

    Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "The first quarter of 2026 was adversely impacted as new Medicare reimbursement policies in the advanced wound care space went into effect at the start of the year and led to significant confusion across the industry in nearly every care setting. Additio

    4/29/26 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

    MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13759618 A replay of the webcast will be available for approximately 30 days on the Company's

    4/22/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Restructuring and Cost Reduction Initiative

    MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organizatio

    4/16/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/12/24 4:04:33 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MiMedx Group Inc

    SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/7/24 10:25:58 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/4/24 1:30:50 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care